Literature DB >> 14967430

Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer.

Chris Parker1, Michael Milosevic, Ants Toi, Joan Sweet, Tony Panzarella, Rob Bristow, Charles Catton, Pamela Catton, Juanita Crook, Mary Gospodarowicz, Michael McLean, Padraig Warde, Richard P Hill.   

Abstract

PURPOSE: To describe the oxygenation of clinically localized prostate cancer. METHODS AND MATERIALS: Intraprostatic oxygen tension was measured using the Eppendorf electrode in 55 unanesthetized men with localized prostate cancer before radiotherapy. Measurements were made along two tracks through regions of suspected tumor in the prostate, and core needle biopsies were then obtained from the same regions.
RESULTS: The median pO(2) ranged from 0.2 to 57.3 mm Hg, and the grand median pO(2) was 4.5 mm Hg. The percentage of oxygen readings <5 mm Hg (HP(5)) ranged from 0% to 100% (median 60%). The track 1 oxygen readings were greater than those from track 2. Statistically significant heterogeneity was found in the individual oxygen readings: the between- and within-tumor components accounted for 32% and 68% of the total variability, respectively. However, the between-tumor variability in HP(5) significantly exceeded the within-tumor variability (61% vs. 39%). No association was found between oxygen values and clinical factors, including age, T stage, Gleason score, prostate-specific antigen level, hemoglobin concentration, or prior hormonal treatment. No difference was noted in the oxygenation between regions of tumor and normal prostate tissue, as determined from the core biopsies.
CONCLUSION: Localized prostate cancer is characterized by marked hypoxia and significant heterogeneity in oxygenation, similar to other human tumors. The normal prostate may contain regions of low oxygen concentration. HP(5), as determined in this study, should adequately discriminate among patients with prostate cancer and allow the independent prognostic significance of oxygenation to be evaluated once the study matures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967430     DOI: 10.1016/S0360-3016(03)01621-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.

Authors:  Susan L Dalrymple; Robyn E Becker; Haoming Zhou; Theodore L DeWeese; John T Isaacs
Journal:  Prostate       Date:  2011-08-11       Impact factor: 4.104

2.  Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques.

Authors:  Rita Garcia-Parra; David Wood; Rajal B Shah; Javed Siddiqui; Hero Hussain; Hyunjin Park; Timothy Desmond; Charles Meyer; Morand Piert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-16       Impact factor: 9.236

3.  Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.

Authors:  David J Carlson; Paul J Keall; Billy W Loo; Zhe J Chen; J Martin Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-22       Impact factor: 7.038

4.  AMP-activated protein kinase promotes human prostate cancer cell growth and survival.

Authors:  Hyeon Ung Park; Simeng Suy; Malika Danner; Vernon Dailey; Ying Zhang; Henghong Li; Daniel R Hyduke; Brian T Collins; Gregory Gagnon; Bhaskar Kallakury; Deepak Kumar; Milton L Brown; Albert Fornace; Anatoly Dritschilo; Sean P Collins
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

5.  Characterization of gradient echo signal decays in healthy and cancerous prostate at 3T improves with a Gaussian augmentation of the mono-exponential (GAME) model.

Authors:  Pelin Aksit Ciris; Mukund Balasubramanian; Ravi T Seethamraju; Junichi Tokuda; Jonathan Scalera; Tobias Penzkofer; Fiona M Fennessy; Clare M Tempany-Afdhal; Kemal Tuncali; Robert V Mulkern
Journal:  NMR Biomed       Date:  2016-05-31       Impact factor: 4.044

Review 6.  Pharmacotherapeutic management of locally advanced prostate cancer: current status.

Authors:  Jarad M Martin; Stephane Supiot; Dominik R Berthold
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 7.  MicroRNAs as putative mediators of treatment response in prostate cancer.

Authors:  Fardod O'Kelly; Laure Marignol; Armelle Meunier; Thomas H Lynch; Antoinette S Perry; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2012-05-22       Impact factor: 14.432

Review 8.  Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance.

Authors:  Christine Levesque; Peter S Nelson
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

Review 9.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

10.  The gene encoding human retinoic acid-receptor-related orphan receptor alpha is a target for hypoxia-inducible factor 1.

Authors:  Caroline Chauvet; Brigitte Bois-Joyeux; Edurne Berra; Jacques Pouyssegur; Jean-Louis Danan
Journal:  Biochem J       Date:  2004-11-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.